More tools:Markets·Screener·Research·Chat

BioXcel Therapeutics, Inc. Common Stock (BTAI) Financial Statements

BioXcel Therapeutics, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00K20GW31
XNAS · usd
0.07▼ 0.04 (-37.11%)
As of 2026-09-04
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close0.12
Day's Range0.07 – 0.09
52-Week Range0.07 – 4.29
Volume47.5M
Avg Volume11.7M
Share Statistics
Shares Outstanding
Employees29
ExchangeXNAS
Listed2018-03-08
Share count as of August 11, 2026
Loading Income Statement…
Key questions about BioXcel Therapeutics, Inc. Common Stock (BTAI)
What is BioXcel Therapeutics, Inc. Common Stock's Market Cap?
BioXcel Therapeutics, Inc. Common Stock's Market Cap is $2.3M, based on as-reported figures from SEC (XBRL) filings.
What is BioXcel Therapeutics, Inc. Common Stock's Enterprise Value?
BioXcel Therapeutics, Inc. Common Stock's Enterprise Value is $93.9M, based on as-reported figures from SEC (XBRL) filings.
What is BioXcel Therapeutics, Inc. Common Stock's Price / Sales?
BioXcel Therapeutics, Inc. Common Stock's Price / Sales is 3.1×, based on as-reported figures from SEC (XBRL) filings.
What is BioXcel Therapeutics, Inc. Common Stock's EV / Revenue?
BioXcel Therapeutics, Inc. Common Stock's EV / Revenue is 126.6×, based on as-reported figures from SEC (XBRL) filings.
What is BioXcel Therapeutics, Inc. Common Stock's EV / EBITDA?
BioXcel Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is BioXcel Therapeutics, Inc. Common Stock's Revenue (TTM)?
BioXcel Therapeutics, Inc. Common Stock's Revenue (TTM) is $742.0K, based on as-reported figures from SEC (XBRL) filings.
What is BioXcel Therapeutics, Inc. Common Stock's Net Income (TTM)?
BioXcel Therapeutics, Inc. Common Stock's Net Income (TTM) is -$70.9M, based on as-reported figures from SEC (XBRL) filings.
What is BioXcel Therapeutics, Inc. Common Stock's EBITDA?
BioXcel Therapeutics, Inc. Common Stock's EBITDA is -$44.7M, based on as-reported figures from SEC (XBRL) filings.
What is BioXcel Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
BioXcel Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -2.26, based on as-reported figures from SEC (XBRL) filings.
What is BioXcel Therapeutics, Inc. Common Stock's EBITDA Margin?
BioXcel Therapeutics, Inc. Common Stock's EBITDA Margin is -6024.4%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
Product revenue, net
YoY growth+51.7%+22.6%-30.1%-54.2%
Operating expenses
Cost of goods sold
Research and development
Selling, general and administrative
Total operating expenses
% of revenue5700.5%5062.6%4116.4%14618.4%
Loss from operations
% of revenue-5600.5%-4962.6%-4016.4%-14518.4%
Other (income) expense
Interest expense
Interest income
Other (income) expense, net
Net loss
% of revenue-8084.1%-6160.7%-4900.4%-31541.8%
Basic net loss per share attributable to common stockholders (in dollars per share)
Diluted net loss per share attributable to common stockholders (in dollars per share)